Leukemia - Table of Contents alert Volume 26 Issue 11

TABLE OF CONTENTS Volume 26, Issue 11 (November 2012) In this issue Leading Article Spotlight Review Review Original Articles Letters to the Editor Corrigenda Also new AOP Advertisement BD Reagents for Blood Cell Disorders Part of the building blocks to support patient care for blood cell disorders, BD Biosciences reagents provide a full spectrum of color choices, allowing you to analyze multiple parameters simultaneously and access a whole new world of information and insight. Welcome to a more colorful worldsm. bdbiosciences.com/go/color Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement 98 days from submission to publication* Scientific Reports is an open access journal publishing technically sound research across all areas of the natural sciences.  Submit your next research to Scientific Reports  *mean time for papers published in September 2012   Leading Article Top Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia C Liu, J D Kawedia, C Cheng, D Pei, C A Fernandez, X Cai, K R Crews, S C Kaste, J C Panetta, W P Bowman, S Jeha, J T Sandlund, W E Evans, C-H Pui and M V Relling Leukemia 2012 26: 2303-2309; advance online publication, April 9, 2012; 10.1038/leu.2012.102 Abstract | Full Text Spotlight Review Top MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte–erythroid progenitor lineage commitment L Zhang, V G Sankaran and H F Lodish Leukemia 2012 26: 2310-2316; advance online publication, May 23, 2012; 10.1038/leu.2012.137 Abstract | Full Text Review Top Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis R L Comenzo, D Reece, G Palladini, D Seldin, V Sanchorawala, H Landau, R Falk, K Wells, A Solomon, A Wechalekar, J Zonder, A Dispenzieri, M Gertz, H Streicher, M Skinner, R A Kyle and G Merlini Leukemia 2012 26: 2317-2325; advance online publication, April 5, 2012; 10.1038/leu.2012.100 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide A Lopez-Girona, D Mendy, T Ito, K Miller, A K Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian, A Mahmoudi, B Cathers, E Rychak, S Gaidarova, R Chen, P H Schafer, H Handa, T O Daniel, J F Evans and R Chopra Leukemia 2012 26: 2326-2335; advance online publication, May 3, 2012; 10.1038/leu.2012.119 Abstract | Full Text Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia C Simioni, L M Neri, G Tabellini, F Ricci, D Bressanin, F Chiarini, C Evangelisti, A Cani, P L Tazzari, F Melchionda, P Pagliaro, A Pession, J A McCubrey, S Capitani and A M Martelli Leukemia 2012 26: 2336-2342; advance online publication, May 22, 2012; 10.1038/leu.2012.136 Abstract | Full Text INFECTIOUS MEDICINE Differential regulation of miR-21 and miR-146a by Epstein–Barr virus-encoded EBNA2 P Rosato, E Anastasiadou, N Garg, D Lenze, F Boccellato, S Vincenti, M Severa, E M Coccia, R Bigi, M Cirone, E Ferretti, A F Campese, M Hummel, L Frati, C Presutti, A Faggioni and P Trivedi Leukemia 2012 26: 2343-2352; advance online publication, April 19, 2012; 10.1038/leu.2012.108 Abstract | Full Text ACUTE LEUKEMIAS High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses S K Metzelder, T Schroeder, A Finck, S Scholl, M Fey, K Götze, Y C Linn, M Kröger, A Reiter, H R Salih, T Heinicke, R Stuhlmann, L Müller, A Giagounidis, R G Meyer, W Brugger, M Vöhringer, P Dreger, M Mori, N Basara, K Schäfer-Eckart, B Schultheis, C Baldus, A Neubauer and A Burchert Leukemia 2012 26: 2353-2359; advance online publication, April 16, 2012; 10.1038/leu.2012.105 Abstract | Full Text Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia M C Chillón, M T Gómez-Casares, C E López-Jorge, C Rodriguez-Medina, A Molines, M E Sarasquete, M Alcoceba, J D G-S Miguel, C Bueno, R Montes, F Ramos, J N Rodríguez, P Giraldo, M Ramírez, R García-Delgado, J L Fuster, M González-Díaz and P Menendez Leukemia 2012 26: 2360-2366; advance online publication, June 18, 2012; 10.1038/leu.2012.161 Abstract | Full Text Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia S Lee, D-W Kim, B-S Cho, J-H Yoon, S-H Shin, S-A Yahng, S-E Lee, K-S Eom, Y-J Kim, N-G Chung, H-J Kim, C-K Min, J-W Lee, W-S Min and C-W Park Leukemia 2012 26: 2367-2374; advance online publication, June 18, 2012; 10.1038/leu.2012.164 Abstract | Full Text NORMAL HEMOPOIESIS Expansion of bone marrow neutrophils following G-CSF administration in mice results in osteolineage cell apoptosis and mobilization of hematopoietic stem and progenitor cells P Singh, P Hu, J Hoggatt, A Moh and L M Pelus Leukemia 2012 26: 2375-2383; advance online publication, April 30, 2012; 10.1038/leu.2012.117 Abstract | Full Text ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier, C Demur, E Lippert, P Pages, V Mansat- De Mas, J Donadieu, F Huguet, N Dastugue, C Broccardo, C Perot and E Delabesse Leukemia 2012 26: 2384-2389; advance online publication, April 19, 2012; 10.1038/leu.2012.109 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells E Cholez, V Debuysscher, J Bourgeais, C Boudot, J Leprince, F Tron, B Brassart, A Regnier, E Bissac, E Pecnard, F Gouilleux, K Lassoued and V Gouilleux-Gruart Leukemia 2012 26: 2390-2397; advance online publication, April 23, 2012; 10.1038/leu.2012.112 Abstract | Full Text MYELOMA Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols S Z Usmani, B Nair, P Qu, E Hansen, Q Zhang, N Petty, S Waheed, J D Shaughnessy, Jr, Y Alsayed, C J Heuck, F van Rhee, T Milner, A Hoering, J Szymonifka, R Sexton, J Sawyer, Z Singh, J Crowley and B Barlogie Leukemia 2012 26: 2398-2405; advance online publication, April 17, 2012; 10.1038/leu.2012.107 Abstract | Full Text A gene expression signature for high-risk multiple myeloma R Kuiper, A Broyl, Y de Knegt, M H van Vliet, E H van Beers, B van der Holt, L el Jarari, G Mulligan, W Gregory, G Morgan, H Goldschmidt, H M Lokhorst, M van Duin and P Sonneveld Leukemia 2012 26: 2406-2413; advance online publication, May 8, 2012; 10.1038/leu.2012.127 Abstract | Full Text Letters to the Editor Top Impact of serum storage conditions on microRNA stability S Grasedieck, N Schöler, M Bommer, J H Niess, H Tumani, A Rouhi, J Bloehdorn, P Liebisch, D Mertens, H Döhner, C Buske, C Langer and Florian Kuchenbauer Leukemia 2012 26: 2414-2416; advance online publication, April 16, 2012; 10.1038/leu.2012.106 Full Text SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome K Siva, P Jaako, K Miharada, E Rörby, M Ehinger, G Karlsson and S Karlsson Leukemia 2012 26: 2416-2419; advance online publication, April 5, 2012; 10.1038/leu.2012.97 Full Text High risks of familial chronic lymphatic leukemia for specific relatives: signposts for genetic discovery? P Rebora, M Lee, K Czene, M G Valsecchi and M Reilly Leukemia 2012 26: 2419-2421; advance online publication, April 16, 2012; 10.1038/leu.2012.103 Full Text Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo V J Craig, A Tzankov, M Flori, C A Schmid, A G Bader and A Müller Leukemia 2012 26: 2421-2424; advance online publication, April 23, 2012; 10.1038/leu.2012.110 Full Text Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow E Van Valckenborgh, E Schouppe, K Movahedi, E De Bruyne, E Menu, P De Baetselier, K Vanderkerken and J A Van Ginderachter Leukemia 2012 26: 2424-2428; advance online publication, April 23, 2012; 10.1038/leu.2012.113 Full Text A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission Y Boumber, H Kantarjian, J Jorgensen, S Wen, S Faderl, R Castoro, J Autry, G Garcia-Manero, G Borthakur, E Jabbour, Z Estrov, J Cortes, J-P Issa and F Ravandi Leukemia 2012 26: 2428-2431; advance online publication, June 5, 2012; 10.1038/leu.2012.153 Full Text Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ−/− mice S Patel, Y Zhang, B Cassinat, F Zassadowski, N Ferré, W Cuccuini, J M Cayuela, P Fenaux, D Bonnet, C Chomienne and F Louache Leukemia 2012 26: 2432-2435; advance online publication, June 13, 2012; 10.1038/leu.2012.154 Full Text IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT M M Pfeiffer, M Schumm, Ingo Müller, R Handgretinger and P Lang Leukemia 2012 26: 2435-2439; advance online publication, June 22, 2012; 10.1038/leu.2012.167 Full Text Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome A Pardanani, A D'Souza, R A Knudson, C A Hanson, R P Ketterling and A Tefferi Leukemia 2012 26: 2439-2441; advance online publication, June 18, 2012; 10.1038/leu.2012.162 Full Text Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL G Hutter, Y Zimmermann, M Rieken, E Hartmann, A Rosenwald, W Hiddemann and M Dreyling Leukemia 2012 26: 2442-2444; advance online publication, May 3, 2012; 10.1038/leu.2012.118 Full Text Corrigenda Top Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide A Lopez-Girona, D Mendy, T Ito, K Miller, A K Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian, A Mahmoudi, B Cathers, E Rychak, S Gaidarova, R Chen, P H Schafer, H Handa, T O Daniel, J F Evans and R Chopra Leukemia 2012 26: 2445; 10.1038/leu.2012.235 Full Text Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding A Seshire, T Rößiger, M Frech, S Beez, H Hagemeyer and E Puccetti Leukemia 2012 26: 2445-2446; 10.1038/leu.2012.170 Full Text Advertisement Ensure your access If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.